Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma.

Sarabi, Matthieu; Mais, Laetitia; Oussaid, Nadia; Desseigne, Françoise; Guibert, Pierre; De La Fouchardiere, Christelle

Sarabi, Matthieu; Mais, Laetitia; Oussaid, Nadia; Desseigne, Françoise; Guibert, Pierre; De La Fouchardiere, Christelle.

Afiliação

Sarabi M; Department of Medical Oncology, Centre Léon Bérard, 69008 Lyon, France.
Mais L; Department of Medical Oncology, Centre Léon Bérard, 69008 Lyon, France.
Oussaid N; Department of Biostatistics, Centre Léon Bérard, 69008 Lyon, France.
Desseigne F; Department of Medical Oncology, Centre Léon Bérard, 69008 Lyon, France.
Guibert P; Department of Medical Oncology, Centre Léon Bérard, 69008 Lyon, France.
De La Fouchardiere C; Department of Medical Oncology, Centre Léon Bérard, 69008 Lyon, France.

Oncol Lett ; 13(6): 4917-4924, 2017 Jun.

Article em En | MEDLINE | ID: mdl-28599496

Palavras-chave

adenocarcinoma; gemcitabine; pancreas; predictive factors; second-line chemotherapy

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: Oncol Lett Ano de publicação: 2017 Tipo de documento: Article País de afiliação: França

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google